Immobilized isocrite dehydrogenase: some aspects of its catalytic, chemical and immunological properties

Isocitrate dehydrogenase from Azotobacter vinelandii has been immobilized on Sepharose 4B with an efficiency of between 60 and 75%. The immobilized enzyme is assayed by a flow technique which monitors a final steady state level of product formation. By the assay system described it is estimated that the immobilized enzyme retains between 30 and 40% of the catalytic activity of the free enzyme. Studies have been carried out on the substrate dependence of the enzyme. The enzyme requires magnesium ions with optimal concentrations of 10⁻³m and above. The dependence on isocitrate and TPN⁺ concentrations was determined and analyzed by double-reciprocal plots. The immobilized enzyme is inactivated by DTNB [5,5′-dithiobis(2-nitrobenzoic acid)] and reactivated by DTT (dithiothreitol). The DTNB-modified enzyme can be reactivated by potassium cyanide. Comparison of these reactions with those of the free enzyme suggest that the steric environment of the active site was not grossly altered by immobilization. Some supporting evidence is derived from the identity of the energies of activation, 16,600 cal/mole, of free and immobilized enzyme catalyzed oxidation of isocitrate. Furthermore, the immobilized enzyme is inactivated by antibody prepared against the free enzyme. The covalently attached enzyme is resistant to tryptic digestion except in the presence of 2 m urea. This suggests that exposed lysyl residues which may be the primary site of attack by trypsin are utilized in immobilization. Treatment of the enzyme with 2 m urea unfolds the enzyme to a conformation which has very little activity but which recovers full activity upon removal of the urea. Interaction of the enzyme with antibody suggest that the antibody reacts univalently. The second valence can be satisfied by addition of free enzyme. The free enzyme bound to the immobilized enzyme-antibody complex is active. Preliminary attempts to dissociate the enzyme-antibody complexes have been unsuccessful.